drugset / Trial / NCT07342738
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
Phase 0
Not yet recruiting
25 enrolled
Sun Yat-sen University
Shanghai Bintie Biotechnology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, Multicenter, open-label clinical study aimed at evaluating the safety and efficacy of TCR-T injection in patients with advanced solid tumors induced by KRAS mutations.
Timeline
- Start
- 2026-02-01
- Primary completion
- 2028-02-01
- Completion
- 2029-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TCR-T cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |